Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
78.27
-0.42 (-0.53%)
4:00:00 PM EDT: $78.24 -0.03 (-0.04%)
Products

Merck Receives Priority Review From FDA For New Drug Application For Hif-2Α Inhibitor Belzutifan (Mk-6482)

Published: 03/16/2021 10:52 GMT
Merck & Co Inc (MRK) - Merck Receives Priority Review From FDA for New Drug Application for Hif-2Α Inhibitor Belzutifan (mk-6482).
Merck Receives Priority Review From FDA for New Drug Application for Hif-2Α Inhibitor Belzutifan (mk-6482).
Merck & Co Inc - FDA Has Set a Prescription Drug User Fee Act (pdufa), Or Target Action, Date of September 15, 2021.